FDA Grants Orphan Drug Designation to Gastric Cancer Treatment, ALT-P7


The US Food and Drug Administration (FDA) has granted an orphan drug designation to Alteogen Inc.’s ALT-P7 for the treatment of patients with gastric cancer.

This US Food and Drug Administration (FDA) has granted an orphan drug designation to Alteogen Inc.’s ALT-P7 for the treatment of patients with gastric cancer.

ALT-P7 is an antibody-drug conjugate (ADC) that utilizes a Trastuzumab variant form of antibody. The potential anti-cancer ADC treatment utilizes the company’s "NexMabTM" platform technology, which is a “next-generation site-specific conjugation methodology developed by the company,” according to the announcement.

"The orphan drug designation of ALT-P7 by the FDA will accelerate the advancement of gastric cancer treatment in the United States," said Soon Jae Park, PhD, CEO of Alteogen, in a recent statement. "We believe that ALT-P7 can provide a breakthrough in the treatment of Her-2 overexpressing gastric cancer, for which there is no effective target treatment yet.”

Currently, ALT-P7 is undergoing a first-in-human phase 1 clinical trial for patients with breast cancer in Korea. The primary outcome measure for the trial is a determination of maximum tolerated dose (MTD) and the dose level showing dose-limiting toxicity (DLT), or determination of recommended phase 2 dose (RP2D) as an alternative to MTD establishment. Secondary outcome measures for the trial include: incidence of treatment-emergent adverse events, a pharmacokinetics test, an immunogenicity test as measured in the timeframe of 4 weeks and an efficacy test as measured at the end of cycle 2; each cycle is 21 days.

For the trial, 7 groups of patients will receive varying doses of ALT-P7. Doses include: 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.4 mg/kg, 3.6 mg/kg, 4.8 mg/kg, and 5.4 mg/kg. Patients will be administered the treatment on day 1 of each 3-week cycle.

The trial is currently enrolling an anticipated 30 participants; December 31, 2018, is the estimated primary completion date. Plans for a phase 2 clinical trial for breast cancer patients is in the works for 2019.

Additionally, Alteogen will extend the clinical development of ALT-P7 for gastric cancer as well, following the current breast cancer trial, which already has proven efficacy in pre-clinical in vitro and in vivo studies.

Related Videos
How Gene and Cell Therapy Is Developing in Dermatology
Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.
The Prospect of Pz-cel in RDEB Treatment, with Peter Marinkovich, MD
Comparing New Therapies for Dystrophic Epidermolysis Bullosa
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Dunia Hatabah, MD | Image Credit: HCPLive
Ricky Safer: What Clinicians Need to Know About PSC
Ryan T. Fischer, MD: Long-Term Odevixibat Benefit for Alagille Syndrome
Saeed Mohammad, MD: IBAT Inhibitors for Cholestatic Disease
Mercedes Martinez, MD: Treatment Strategies for Autoimmune Hepatitis
© 2024 MJH Life Sciences

All rights reserved.